A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation

Overview

Journal Stat Med

Publisher Wiley

Specialty Public Health

Date 2014 May 13

PMID 24817556

Citations 15

Authors

Chunyan Cai

Suyu Liu

Ying Yuan

Affiliations

Soon will be listed here.

Abstract

Interim monitoring is routinely conducted in phase II clinical trials to terminate the trial early if the experimental treatment is futile. Interim monitoring requires that patients' responses be ascertained shortly after the initiation of treatment so that the outcomes are known by the time the interim decision must be made. However, in some cases, response outcomes require a long time to be assessed, which causes difficulties for interim monitoring. To address this issue, we propose a Bayesian trial design to allow for continuously monitoring phase II clinical trials in the presence of delayed responses. We treat the delayed responses as missing data and handle them using a multiple imputation approach. Extensive simulations show that the proposed design yields desirable operating characteristics under various settings and dramatically reduces the trial duration.

Citing Articles

The Win Ratio Approach in Bayesian Monitoring for Two-Arm Phase II Clinical Trial Designs With Multiple Time-To-Event Endpoints.

Huang X, Wang J, Ning J Stat Med. 2024; 43(30):5922-5934.

PMID: 39582325 PMC: 11645213. DOI: 10.1002/sim.10282.

Bayesian sequential monitoring strategies for trials of digestive cancer therapeutics.

Mulier G, Lin R, Aparicio T, Biard L BMC Med Res Methodol. 2024; 24(1):154.

PMID: 39030498 PMC: 11526600. DOI: 10.1186/s12874-024-02278-3.

A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies.

Tian F, Lin R, Wang L, Yuan Y Stat Methods Med Res. 2024; 33(6):931-944.

PMID: 38573788 PMC: 11162096. DOI: 10.1177/09622802241239268.

A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.

Chi X, Yuan Y, Yu Z, Lin R Biom J. 2024; 66(2):e2300122.

PMID: 38368277 PMC: 11323483. DOI: 10.1002/bimj.202300122.

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison.

Zang Y, Thall P, Yuan Y Biometrics. 2024; 80(1).

PMID: 38364811 PMC: 10873567. DOI: 10.1093/biomtc/ujad022.

References

Follmann D, Albert P . Bayesian monitoring of event rates with censored data. Biometrics. 2001; 55(2):603-7. DOI: 10.1111/j.0006-341x.1999.00603.x. View

Zhao L, Taylor J, Schuetze S . Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint. Stat Med. 2012; 31(17):1804-20. PMC: 4167619. DOI: 10.1002/sim.4511. View

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

Heitjan D . Bayesian interim analysis of phase II cancer clinical trials. Stat Med. 1997; 16(16):1791-802. DOI: 10.1002/(sici)1097-0258(19970830)16:16<1791::aid-sim609>3.0.co;2-e. View

Hanfelt J, Slack R, Gehan E . A modification of Simon's optimal design for phase II trials when the criterion is median sample size. Control Clin Trials. 1999; 20(6):555-66. DOI: 10.1016/s0197-2456(99)00028-8. View

Wathen J, Thall P, Cook J, Estey E . Accounting for patient heterogeneity in phase II clinical trials. Stat Med. 2007; 27(15):2802-15. PMC: 5708894. DOI: 10.1002/sim.3109. View

Green S, Dahlberg S . Planned versus attained design in phase II clinical trials. Stat Med. 1992; 11(7):853-62. DOI: 10.1002/sim.4780110703. View

Jung S, Carey M, Kim K . Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials. 2001; 22(4):367-72. DOI: 10.1016/s0197-2456(01)00142-8. View

Ensign L, Gehan E, Kamen D, Thall P . An optimal three-stage design for phase II clinical trials. Stat Med. 1994; 13(17):1727-36. DOI: 10.1002/sim.4780131704. View

10.

Fleming T . One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38(1):143-51. View

11.

Thall P, Simon R, Estey E . Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995; 14(4):357-79. DOI: 10.1002/sim.4780140404. View

12.

Lin Y, Shih W . Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics. 2004; 60(2):482-90. DOI: 10.1111/j.0006-341X.2004.00193.x. View

13.

Tan S, Machin D . Bayesian two-stage designs for phase II clinical trials. Stat Med. 2002; 21(14):1991-2012. DOI: 10.1002/sim.1176. View

14.

Gehan E . The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961; 13:346-53. DOI: 10.1016/0021-9681(61)90060-1. View

15.

Sambucini V . A Bayesian predictive two-stage design for phase II clinical trials. Stat Med. 2007; 27(8):1199-224. DOI: 10.1002/sim.3021. View

16.

Thall P, Simon R . Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994; 50(2):337-49. View

17.

Zohar S, Teramukai S, Zhou Y . Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemp Clin Trials. 2008; 29(4):608-16. DOI: 10.1016/j.cct.2007.11.005. View

18.

Cheung Y, Thall P . Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics. 2002; 58(1):89-97. DOI: 10.1111/j.0006-341x.2002.00089.x. View

19.

Lee J, Liu D . A predictive probability design for phase II cancer clinical trials. Clin Trials. 2008; 5(2):93-106. PMC: 5626665. DOI: 10.1177/1740774508089279. View

20.

Johnson V, Cook J . Bayesian design of single-arm phase II clinical trials with continuous monitoring. Clin Trials. 2009; 6(3):217-26. DOI: 10.1177/1740774509105221. View